© 2020 MJH Life Sciences and OncLive. All rights reserved.
January 17, 2013
Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
September 19, 2011
Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy
September 09, 2011
Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene
September 01, 2011
Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials